Seeking Alpha

Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim...

Shares of BioLineRX (BLRX -15%) tank after the drug developer repeats its plan to report interim results from Phase II/III testing of its acute schizophrenia treatment BL-1020 during the week of March 18, amid speculation of less-than-stellar results. The interim analysis will be performed by a fully independent, external Data Monitoring Committee.
Comments (1)
  • alexrotolo
    , contributor
    Comment (1) | Send Message
     
    I didn't read anything that said there was speculation of less-than-stellar results. Nor was the -15% due to the PR release considering it traded down in Tel Aviv before it even came out.
    4 Feb 2013, 02:36 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector